

ASX Announcement



6 October 2023

Notice of Annual General Meeting and Closing Date for Director Nominations

Perth, Australia, and Minneapolis, USA: Medibio Limited (MEB or the Company) (ASX: MEB) (OTCPINK: MDBIF) advises that the Company's Annual General Meeting (AGM) is scheduled to be convened at 9.00am (WST) on Wednesday, 29 November 2023.

The AGM will be at COMO The Treasury, Executive Boardroom, 1 Cathedral Avenue, Perth Western Australia.

In accordance with the Company's Constitution, the closing date for receipt of director nominations to the Company from persons wishing to be considered for election as a director, is Wednesday, 18 October 2023. Any nominations must be received in writing at the Company's registered office by 5.00pm (WST).

The AGM materials will be produced and provided to shareholders in due course.

This announcement is authorised for release by the Board of Directors of Medibio Limited.

ENDS

Investor Enquiries:

investors@medibio.com.au

Henry Jordan – Six Degrees Investor Relations

Henry.jordan@sdir.com.au

+61 431 271 538

About Medibio Limited

Medibio (ASX: MEB) (OTCPINK: MDBIF) is a mental health technology company pioneering the use of objective measures to aid in the early detection and screening of mental health conditions. Through their Corporate Health product, the Company offers mental well-being solutions for businesses and are also developing products to serve the healthcare provider market. The Company was founded in Australia, with offices located in Perth (Western Australia) and Minneapolis (MN, USA). Medibio is listed on the Australian Securities Exchange Ltd and trades on the OTCQB Venture Market. Investors can find additional information on www.otcmarkets.com and www.asx.com.au.